ESSA Pharma (EPIX) shares plunged 70% in recent Friday premarket activity, a day after saying it planned to terminate a phase 2 clinical study evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide.
Lexicon Pharmaceuticals (LXRX) stock tumbled 37%, after saying late Thursday that the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee said the company's Zynquista inhibitor's benefits do not "outweigh" the risks in adults having type 1 diabetes and chronic kidney disease.
DigitalBridge Group (DBRG) shares were down 6% after it reported lower Q3 distributable earnings and total revenue compared with a year earlier.
Telephone and Data Systems (TDS) stock slipped nearly 6% after it reported a wider Q3 net loss and lower revenue compared with last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。